US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Sinovac Biotech

6.47

0.0000

Volume:- -

Turnover:- -

Market Cap:464.94M

PE:-4.72

High:6.47

Open:6.47

Low:6.47

Close:6.47

52wk High:6.47

52wk Low:6.47

Shares:71.86M

Float Shares:31.17M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.3700

EPS(LYR):1.06

ROE:25.15%

ROA:11.46%

PB:0.62

PE(LYR):6.13

Loading ...

Overview Company News Filings

Sinovac Biotech Reports Nearly 30% Surge in First-Half Overseas Revenue, Mitigating Domestic Market Decline

Sinovac Biotech H1 Adj. EPS $0.06 Down From $1.18 YoY, Sales $130.270M Up From $128.711M YoY

Benzinga Earnings

Sinovac FY25 H1 swings to net loss of $21.7 million; net sales rise 1.21% to $130.3 million

Sinovac Reports Unaudited First Half of 2025 Financial Results

THOMSON REUTERS

Press Release: SINOVAC Reports Unaudited First Half of 2025 Financial Results

Sinovac corrects typo in Note 2 sub-numbering in 2024 annual report

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 10:36 AM

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 01:05 PM

Sinovac delays filing 2025 annual report after prior-year financial restatements

Sinovac FY24 net income drops to $40.7 million; net sales fall 23.1% to $361.4 million

Sinovac Biotech director Li Jiaqiang files initial beneficial ownership statement

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:53 PM

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 11:18 AM

Sinovac Biotech Ltd. Director Fu Shan files initial beneficial ownership statement

Sinovac Biotech files Form 3 initial beneficial ownership statement for Director Andrew Y. Yan

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 04:00 AM

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/SVA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVA\",,,,,undefined,":{"symbol":"SVA","market":"US","secType":"STK","nameCN":"Sinovac Biotech","latestPrice":6.47,"timestamp":1788206400000,"preClose":6.47,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":31169000,"shares":71860702,"eps":-1.37,"marketStatus":"Halted","change":0,"latestTime":"08-31 18:52:09 EDT","open":6.47,"high":6.47,"low":6.47,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.37,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1102482000000,"exchange":"NASDAQ","adjPreClose":6.47,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVA\",,,,,undefined,":{"symbol":"SVA","floatShares":31169000,"roa":"11.46%","roe":"25.15%","lyrEps":1.055174,"shares":71860702,"dividePrice":0,"high":6.47,"amplitude":0,"preClose":6.47,"low":6.47,"week52Low":6.47,"pbRate":"0.62","week52High":6.47,"institutionHeld":0.1883,"latestPrice":6.47,"eps":-1.37,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.37,"open":6.47,"prevYearClose":6.47,"prevWeekClose":6.47,"prevMonthClose":6.47,"prevQuarterClose":6.47,"fiveDayClose":6.47,"twentyDayClose":6.47,"sixtyDayClose":6.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SVA\",params:#limit:5,,,undefined,":[{"date":"2025-07-08","symbol":"SVA","amount":55,"announcedDate":"2025-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1751981400000,"name":"科兴生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-07","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1751947200000,"payDate":"2025-07-07"},{"market":"US","date":"2022-04-29","symbol":"SVA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1651204800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-12-31","symbol":"SVA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1640926800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-09-17","symbol":"SVA","fiscalQuarterEnding":"2021/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1631851200000,"reportTimeType":"post","actualEps":-0.05},{"market":"US","date":"2021-06-29","symbol":"SVA","fiscalQuarterEnding":"2021/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1624939200000,"reportTimeType":"","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SVA\",market:\"US\",,,undefined,":[{"executeDate":"2025-07-08","recordDate":"2025-05-23","paymentDate":"2025-07-07","value":55,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SVA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SVA","date":"2021-09-21","current":-4.722628,"percent":0.24257,"low":-100.201212,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"high":42.074882,"avg":0.136365,"sd":42.133061,"marketCap":642436987},"quantilePoints":[{"date":"2021-09-03","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-10","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-17","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-24","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-01","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-08","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-15","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-22","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-29","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-11-05","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-11-09","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987}],"updateTime":1788216730003},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SVA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1161362237","title":"Sinovac Biotech Reports Nearly 30% Surge in First-Half Overseas Revenue, Mitigating Domestic Market Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1161362237","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161362237?lang=en_us&edition=fundamental","pubTime":"2026-05-09 09:21","pubTimestamp":1778289687,"startTime":"0","endTime":"0","summary":"Sinovac Biotech's (SVA) 2025 interim report highlights a significant shift in its business focus. The financial results indicate a 29.4% year-over-year increase in the company's overseas sales for...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634676084","title":"Sinovac Biotech H1 Adj. EPS $0.06 Down From $1.18 YoY, Sales $130.270M Up From $128.711M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2634676084","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634676084?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:08","pubTimestamp":1778274480,"startTime":"0","endTime":"0","summary":"Sinovac Biotech (NASDAQ:SVA) reported quarterly earnings of $0.06 per share. This is a 94.92 percent decrease over earnings of $1.18 per share from the same period last year.  The company reported $130.270 million in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52431243/sinovac-biotech-h1-adj-eps-0-06-down-from-1-18-yoy-sales-130-270m-up-from-128-711m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634673184","title":"Sinovac FY25 H1 swings to net loss of $21.7 million; net sales rise 1.21% to $130.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634673184","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634673184?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:00","pubTimestamp":1778274057,"startTime":"0","endTime":"0","summary":"Sinovac Biotech posts net loss attributable to common shareholders of USD 21.7 million, or USD 0.30 per diluted share.Net sales edge up 1.21% to USD 130.3 million.Gross margin climbs 8.5 percentage points to 62.5%.Loss on disposal and impairment widens to USD 69.9 million, including USD 68.1 million tied to IPR&D and goodwill from a rabies-vaccine subsidiary acquisition.CEO Weidong Yin flags growth in Latin America and Southeast Asia offsetting softer demand in Chinese Mainland, citing wins in Chile’s influenza vaccine tender for 2025-26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via Business Wire  on May 08, 2026, and is solely responsible for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL73WcJv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634678974","title":"Sinovac Reports Unaudited First Half of 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634678974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634678974?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:00","pubTimestamp":1778274000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA5KSTMC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634324467","title":"Press Release: SINOVAC Reports Unaudited First Half of 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634324467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634324467?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:00","pubTimestamp":1778274000,"startTime":"0","endTime":"0","summary":"Sinovac Biotech Ltd.  , a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2025.--  Sales for the six months ended June 30, 2025 were $130.3 million,compared to $128.7 million in the prior year period.--  The Company posted $21.7 million of net loss attributable to common. shareholders, or a loss of $0.30 per basic and diluted share, in the six. months ended June 30, 2025, compared to net income attributable to common. shareholders of $93.9 million, or an income of $1.31 per basic and. --  Mr. Weidong Yin, CEO of SINOVAC, commented, \"amidst a complex global. am pleased to witness the robust growth in emerging markets across Latin. America and Southeast Asia, which has effectively offset the slowdown of. vaccine demand in the Chinese Mainland market. Beyond commercial. From the marketing approval of the adsorbed tetanus vaccine to the. The Company continues to prioritize research and development as","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139","PDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633465421","title":"Sinovac corrects typo in Note 2 sub-numbering in 2024 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2633465421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633465421?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:17","pubTimestamp":1778152663,"startTime":"0","endTime":"0","summary":"Sinovac Biotech filed a Form 6-K to correct a typographical error in Note 2 of its annual report on Form 20-F for fiscal year ended Dec. 31, 2024, originally filed April 30, 2026.Sub-numbering on pages F-13 and F-14 was incorrectly shown as “1” through “10” instead of “A” through “J,” matching references in related tables elsewhere in Note 2.No changes were made to financial statements or other disclosures, with report continuing to speak as of initial filing date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 07, 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLblH9g5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633134374","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 10:36 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2633134374","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633134374?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:36","pubTimestamp":1778078175,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 10:36 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nAQN2LXXE2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633990532","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:58 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2633990532","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633990532?lang=en_us&edition=fundamental","pubTime":"2026-05-05 15:58","pubTimestamp":1777967883,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:58 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nAQN2LXN2Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632646402","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 01:05 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2632646402","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632646402?lang=en_us&edition=fundamental","pubTime":"2026-05-02 01:05","pubTimestamp":1777655100,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 01:05 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nAQN2LXCAV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631655202","title":"Sinovac delays filing 2025 annual report after prior-year financial restatements","url":"https://stock-news.laohu8.com/highlight/detail?id=2631655202","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631655202?lang=en_us&edition=fundamental","pubTime":"2026-04-30 22:17","pubTimestamp":1777558674,"startTime":"0","endTime":"0","summary":"Sinovac reported it will miss filing deadline for its annual report on Form 20-F for fiscal year ended Dec. 31, 2025.Company expects to file within 15 calendar days of prescribed due date.Grant Thornton said its prior audit opinions for fiscal years 2021-2023 should no longer be relied upon.Sinovac appointed Zhonghua Certified Public Accountants on Dec. 31, 2025, citing planned restatements for fiscal years 2021-2023 that it said will delay the 2025 filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL4JTd7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631218655","title":"Sinovac FY24 net income drops to $40.7 million; net sales fall 23.1% to $361.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631218655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631218655?lang=en_us&edition=fundamental","pubTime":"2026-04-30 22:15","pubTimestamp":1777558556,"startTime":"0","endTime":"0","summary":"Sinovac posted net income of USD 40.66 million, swinging from a loss a year earlier.Operating loss narrowed to USD 505.54 million, improving from the prior year.Gross margin slipped 7.7 percentage points to 61.1% due to selling price decreases net of cost-reduction and efficiency efforts.Management said 2024 revenue decline was driven by lower quadrivalent influenza vaccine volume on intense competition, plus reduced mumps vaccine production.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL3cR3Xq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628277900","title":"Sinovac Biotech director Li Jiaqiang files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2628277900","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628277900?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:10","pubTimestamp":1776420641,"startTime":"0","endTime":"0","summary":"Sinovac Biotech director Li Jiaqiang filed an initial beneficial ownership statement reporting indirect ownership of 18,515,315 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLbmwZng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775903","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:53 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775903","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775903?lang=en_us&edition=fundamental","pubTime":"2026-03-21 03:53","pubTimestamp":1774036412,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:53 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nAQN2LR6WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620224966","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 11:18 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2620224966","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620224966?lang=en_us&edition=fundamental","pubTime":"2026-03-19 23:18","pubTimestamp":1773933520,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 11:18 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nAQN2LQZWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253926","title":"Sinovac Biotech Ltd. Director Fu Shan files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253926","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253926?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:12","pubTimestamp":1773835945,"startTime":"0","endTime":"0","summary":"Sinovac reported that director Shan Fu filed an initial statement of beneficial ownership. The filing reported 5.9 million common shares held indirectly. The shares were held through Vivo Capital Fund VIII, Vivo Capital Surplus Fund VIII, and Vivo Capital Fund IX.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8v9Cwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253687","title":"Sinovac Biotech files Form 3 initial beneficial ownership statement for Director Andrew Y. Yan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253687","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253687?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:07","pubTimestamp":1773835638,"startTime":"0","endTime":"0","summary":"Sinovac reported an initial statement of beneficial ownership by director Andrew Yan. The filing reported 10,780,820 common shares held indirectly. The shares were reported as held through SAIF Partners IV L.P.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLc3v8Px:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620233359","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 04:00 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2620233359","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620233359?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:00","pubTimestamp":1773820802,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 04:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nAQN2LQO64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619843075","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:58 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2619843075","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619843075?lang=en_us&edition=fundamental","pubTime":"2026-03-16 15:58","pubTimestamp":1773647880,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:58 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nAQN2LQDAI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617619876","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:28 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2617619876","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617619876?lang=en_us&edition=fundamental","pubTime":"2026-03-08 15:28","pubTimestamp":1772954909,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:28 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260308:nAQN2LPALE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":79,"code":"91000000","status":"200"}]}}